Prospective Multi-center Study to Evaluate the Safety and Effectiveness of the OR3O Dual Mobility System in Primary and Revision Total Hip Arthroplasty (THA) Procedures

Brief description of study

The purpose of this study is to assess the safety and effectiveness of the OR3O™ Dual Mobility System in primary (the first time your hip is being replaced) or revision (replacing parts in your hip which were replaced previously) hip replacement. The performance of the OR3O system will be followed over a ten year period. The OR3O™ Dual Mobility System has been cleared by the United States Food and Drug Administration (FDA) and by Health Canada for use in hip replacement and is commercially available in the United States and Canada.


Clinical Study Identifier: s20-00373
ClinicalTrials.gov Identifier: NCT04325022
Principal Investigator: Ran R Schwarzkopf.


If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.